Home LiteratureArticle Details
PMID: 15118844 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.

MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide.

European journal of nuclear medicine and molecular imaging ·Vol. 31 ·No. 8 ·2004-08-00 ·Pages 1081-9

Chen X, Park R, Hou Y, Khankaldyyan V, Gonzales-Gomez I, Tohme M, Bading JR, Laug WE, Conti PS

Abstract

We have previously labeled cyclic RGD peptide c(RGDyK) with fluorine-18 through conjugation labeling via a prosthetic 4-[18F]fluorobenzoyl moiety and applied this [18F]FB-RGD radiotracer for alphav-integrin expression imaging in different preclinical tumor models with good tumor-to-background contrast. However, the unfavorable hepatobiliary excretion and rapid tumor washout rate of this tracer limit its potential clinical applications. The aims of this study were to modify the [18F]FB-RGD tracer by inserting a heterobifunctional poly(ethylene glycol) (PEG, M.W. =3,400) between the 18F radiolabel and the RGD moiety and to test this [18F]FB-PEG-RGD tracer for brain tumor targeting and in vivo kinetics. [18F]FB-PEG-RGD was prepared by coupling the RGD-PEG conjugate with N-succinimidyl 4-[18F]fluorobenzoate ([18F]SFB) under slightly basic conditions (pH=8.5). The radiochemical yield was about 20-30% based on the active ester [18F]SFB, and specific activity was over 100 GBq/micromol. This tracer had fast blood clearance, rapid and high tumor uptake in the subcutaneous U87MG glioblastoma model (5.2+/-0.5%ID/g at 30 min p.i.). Moderately rapid tumor washout was observed, with the activity accumulation decreased to 2.2+/-0.4%ID/g at 4 h p.i. MicroPET and autoradiography imaging showed a very high tumor-to-background ratio and limited activity accumulation in the liver, kidneys and intestinal tracts. U87MG tumor implanted into the mouse forebrain was well visualized with [18F]FB-PEG-RGD. Although uptake in the orthotopic tumor was significantly lower (P<0.01) than in the subcutaneous tumor, the maximum tumor-to-brain ratio still reached 5.0+/-0.6 due to low normal brain background. The results of H&E staining post mortem agreed with the anatomical information obtained from non-invasive microPET imaging. In conclusion, PEGylation suitably modifies the physiological behavior of the RGD peptide. [18F]FB-PEG-RGD gave improved tumor retention and in vivo kinetics compared with [18F]FB-RGD.

MeSH Terms
Animals Brain/blood supply,diagnostic imaging,metabolism Brain Neoplasms/diagnostic imaging,metabolism Female Glioblastoma/diagnostic imaging,metabolism Metabolic Clearance Rate Mice Mice, Nude Neovascularization, Pathologic/diagnostic imaging,metabolism Organ Specificity Peptides, Cyclic/pharmacokinetics Polyethylene Glycols/pharmacokinetics Positron-Emission Tomography/methods Radiopharmaceuticals/pharmacokinetics Tissue Distribution Whole-Body Counting
Chemicals
4-fluorobenzoyl-polyethylene glycol-cyclo(arginyl-glycyl-aspartyl-tyrosyl-lysyl) Peptides, Cyclic Radiopharmaceuticals Polyethylene Glycols
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Chen Xiaoyuan
PET Imaging Science Center, Department of Radiology, University of Southern California Keck School of Medicine, 1510 San Pablo St., Suite 350, CA 90033, Los Angeles, USA.
Park Ryan
Hou Yingping
Khankaldyyan Vazgen
Gonzales-Gomez Ignacio
Tohme Michel
Bading James R
Laug Walter E
Conti Peter S
References (33)
33 references, click to expand
  1. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting.
    Cancer Biother Radiopharm. 2002 Dec;17 (6):641-6 PMID: 12537667
  2. Direct electrophilic radiofluorination of a cyclic RGD peptide for in vivo alpha(v)beta3 integrin related tumor imaging.
    Nucl Med Biol. 2003 Jan;30(1):1-9 PMID: 12493537
  3. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy.
    Int J Cancer. 2000 Aug 20;90(4):186-98 PMID: 10993959
  4. Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting.
    J Nucl Med. 1999 Jun;40(6):1061-71 PMID: 10452325
  5. A comparative study of N.C.A. fluorine-18 labeling of proteins via acylation and photochemical conjugation.
    Nucl Med Biol. 1996 Apr;23(3):365-72 PMID: 8782249
  6. Angiogenesis in brain tumors.
    Microsc Res Tech. 2003 Feb 1;60(2):225-30 PMID: 12539176
  7. Chemistry for peptide and protein PEGylation.
    Adv Drug Deliv Rev. 2002 Jun 17;54(4):459-76 PMID: 12052709
  8. Molecular epidemiology of glioblastoma.
    Cancer J. 2003 Mar-Apr;9(2):99-106 PMID: 12784875
  9. Cytostatic Agents in the Management of Malignant Gliomas.
    Cancer Control. 1998 Mar;5(2):150-162 PMID: 10761026
  10. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging.
    Nat Med. 1998 May;4(5):623-6 PMID: 9585240
  11. Effect of pegylation on pharmaceuticals.
    Nat Rev Drug Discov. 2003 Mar;2(3):214-21 PMID: 12612647
  12. Labeling proteins at high specific activity using N-succinimidyl 4-[18F](fluoromethyl) benzoate.
    Appl Radiat Isot. 1997 Feb;48(2):169-73 PMID: 9219343
  13. alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin.
    Int J Cancer. 2002 Apr 10;98(5):690-7 PMID: 11920637
  14. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
    Cancer Res. 2002 Nov 1;62(21):6146-51 PMID: 12414640
  15. Glial tumors--new approaches in chemotherapy.
    J Neurosci Nurs. 2002 Dec;34(6):326-30 PMID: 12506816
  16. The uses and properties of PEG-linked proteins.
    Crit Rev Ther Drug Carrier Syst. 1992;9(3-4):249-304 PMID: 1458545
  17. Current and future strategies for the treatment of malignant brain tumors.
    Pharmacol Ther. 2003 Apr;98(1):71-108 PMID: 12667889
  18. Synthesis of 2'-fluoro-5-[11C]-methyl-1-beta-D-arabinofuranosyluracil ([11C]-FMAU): a potential nucleoside analog for in vivo study of cellular proliferation with PET.
    Nucl Med Biol. 1995 Aug;22(6):783-9 PMID: 8535339
  19. Targeted molecular therapy of GBM.
    Brain Pathol. 2003 Jan;13(1):52-61 PMID: 12580545
  20. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography.
    Cancer Res. 2001 Mar 1;61(5):1781-5 PMID: 11280722
  21. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist.
    Neurosurgery. 2001 Jan;48(1):151-7 PMID: 11152340
  22. Anti-angiogenic agents for the treatment of brain tumors.
    Neuroimaging Clin N Am. 2002 Nov;12(4):477-99 PMID: 12687907
  23. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics.
    J Nucl Med. 2001 Feb;42(2):326-36 PMID: 11216533
  24. In vitro and in vivo evaluation of a Technetium-99m-labeled cyclic RGD peptide as a specific marker of alpha(V)beta(3) integrin for tumor imaging.
    Bioconjug Chem. 2002 May-Jun;13(3):561-70 PMID: 12009947
  25. N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists.
    J Med Chem. 1999 Aug 12;42(16):3033-40 PMID: 10447947
  26. Role of angiogenesis in tumor growth and metastasis.
    Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8 PMID: 12516034
  27. Fluorine-18 labeling of proteins.
    J Nucl Med. 1987 Apr;28(4):462-70 PMID: 3494825
  28. New perspectives in cell adhesion: RGD and integrins.
    Science. 1987 Oct 23;238(4826):491-7 PMID: 2821619
  29. Pegylation: a novel process for modifying pharmacokinetics.
    Clin Pharmacokinet. 2001;40(7):539-51 PMID: 11510630
  30. Positron emission tomography imaging of brain tumors.
    Neuroimaging Clin N Am. 2002 Nov;12 (4):615-26 PMID: 12687915
  31. Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation.
    Nucl Med Biol. 2004 Jan;31(1):11-9 PMID: 14741566
  32. Anti-angiogenic therapy: rationale, challenges and clinical studies.
    Angiogenesis. 2002;5(4):237-56 PMID: 12906317
  33. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography.
    Nat Med. 1998 Nov;4(11):1334-6 PMID: 9809561
Article Info
Journal
European journal of nuclear medicine and molecular imaging
Abbr.
Eur J Nucl Med Mol Imaging
ISSN
1619-7070
Published
2004-08-00
Epub
2004-00-29
Pages
1081-9
Language
English
Region
Germany
NLM ID
101140988
Subset
IM
Grants
NCI NIH HHS · P20 CA86532 · United States
NCI NIH HHS · R01 CA82989 · United States
NIBIB NIH HHS · R21 EB001785 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com